HK Stock Market Move | SISRAM MED (01696) fell nearly 6%, expecting to turn from profit to loss in the first half of the year due to a challenging environment in the North American market and declining sales.

SISRAM MED (01696) fell nearly 6%, and as of the time of writing, it has declined by 5.87%, trading at HKD 2.325, with a turnover of HKD 1.6653 million. In terms of news, on August 3, SISRAM MED issued a profit warning. The group expects its revenue for the first half of 2026 to be no less than USD 171 million, compared to USD 166 million in the same period of 2025, but it anticipates a loss attributable to the owners of the company of approximately USD 900,000 to USD 1.4 million, marking a shift from a profit of USD 6.4 million in the same period last year. The primary reasons for the loss include continued severe operating conditions in the North American market leading to a decline in sales, as well as the company's ongoing investment in its injection and filling business in mainland China. The company stated that it is optimizing its commercialization efficiency in North America, advancing cost control, and accelerating the promotion of the DAXIF product and the development of local production capacity in China.